Invest Like Warren Buffett by Buying WELL Health Stock

The pandemic has boosted the digitization trend in healthcare, which is beneficial for WELL Health Technologies (TSX:WELL) stock.

| More on:
healthcare pharma

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Warren Buffett recently made important bets in the health sector. His Berkshire Hathaway conglomerate bought US$5.7 billion worth in shares in four U.S. pharmaceutical companies in the third quarter: AbbVie, Bristol-Myers Squibb, Merck, and Pfizer. The company already had stakes in Biogen, Johnson & Johnson, Teva Pharmaceuticals, and DaVita, a kidney dialysis company. Another healthcare stock that could interest Warren Buffett and that could also interest you is WELL Health Technologies (TSX:WELL). Here’s why WELL Health stock is a good buy in the healthcare sector.

WELL Health business is growing fast

The COVID-19 pandemic accelerated the digital transformation of healthcare. WELL Health, a healthcare company that leverages technology to support patients and doctors, has seen its business grow strongly in the past few months.

WELL Health has a rapidly growing digital portfolio of healthcare assets. It has approximately 2,000 clinics serving more than 10,000 medical practitioners across the country. The company’s portfolio of clinics is also growing in importance. It has 19 wholly owned clinics and approximately 180 physicians in these clinics. WELL Health launched in March VirtualClinic+, a digital healthcare communication platform that connects patients to physicians via video, phone, and secure messaging.

The most recent results from WELL Health show that the business is growing fast. Indeed, revenue increased by 50% in the third quarter.

WELL Health achieved digital services revenue of $2.48 million, up 149% year over year. The company’s positive third-quarter results were driven by a significant increase in its clinical patient services revenue from the second quarter of 2020 to the third quarter of 2020 due to a return to physical clinic visits after lockdowns related to COVID-19. At the same time, WELL Health’s virtual care revenue continued to grow in the quarter.

Over the past few months, WELL Health has continued to grow with a number of key acquisitions. These acquisitions have diversified WELL Health’s business and increased its market share and reach.

For example, the healthcare company acquired earlier this month DoctorCare, which provides billing and back-office services to physicians. WELL Health also recently completed the acquisition of Insig Corporation, a leading Canadian virtual care platform. In August, WELL Health acquired the services division of Cycura, a Toronto-based cybersecurity startup, to protect personal health information.

The company entered the U.S. market in September via the acquisition of a majority stake in Circle Medical, a U.S.-based telemedicine provider.

WELL Health stock will do well in the coming years

WELL Health stock has been one of the top performers on the TSX in 2020. The stock has risen by more than 350% since the start of the year and is up about 6,345% since its IPO in 2016.

As the second wave of the pandemic hits North America, WELL Health stock is well positioned to progress in the months to come.

WELL Health stock could easily double or triple in the next two years. The company posted strong earnings in the third quarter. The management team is able to strategically acquire companies that complement its corporate structure. Plus, WELL Health has no debt on its balance sheet. WELL Health stock is clearly poised for success in the healthcare sector.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf owns shares of AbbVie and Merck. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares) and Bristol Myers Squibb. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short December 2020 $210 calls on Berkshire Hathaway (B shares).

More on Investing

Investing

KM Throwaway Post

Read more »

Investing

Carlos Test Yoast Metadata

Read more »

Investing

KM Ad Test

This is my excerpt.

Read more »

Investing

Test post for affiliate partner mockups

Updated: 9/17/2024. This post was not sponsored. The views and opinions expressed in this review are purely those of the…

Read more »

Investing

Testing Ecap Error

Premium content from Motley Fool Stock Advisor We here at Motley Fool Stock Advisor believe investors should own at least…

Read more »

Investing

TSX Today: Testing the Ad for James

la la la dee dah.

Read more »

Lady holding remote control pointed towards a TV
Investing

2 Streaming Stocks to Buy Now and 1 to Run From

There are streaming stocks on the TSX that are worth paying attention to in 2023 and beyond.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Stocks for Beginners

Top Recession-Resilient TSX Stocks to Buy With $3,000

It's time to increase your exposure to defensives!

Read more »